Rigel Pharmaceuticals RIGL Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's interest expense?
- Rigel Pharmaceuticals (RIGL) reported interest expense of $1.43M in Q1 2026.
- How has Rigel Pharmaceuticals's interest expense changed year-over-year?
- Rigel Pharmaceuticals's interest expense decreased by 22.7% year-over-year, from $1.85M to $1.43M.
- What is the long-term trend for Rigel Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's interest expense has grown at a 10.8% compound annual growth rate (CAGR), from $4.86M to $7.32M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.